NRX-100 is an IV ketamine formulation being submitted to regulators as an alternative treatment for acute suicidal crises in certain types of depression.
Publications and Scientific Updates
Mar. 24, 2025
NRX-100’s Breakthrough in Suicidality Treatment
Aug. 29, 2024
How NRx Could Upend the Fight Against Depression and Suicide
What Are NRX-101 and NRX-100? It’s against this backdrop that NRx Pharmaceuticals sought to develop two new pharmacological treatments for bipolar depression with a risk of suicide.
Aug. 1, 2022
Scientific Update from NRx Pharmaceuticals Chief Scientist, Jonathan Javitt, MD, MPH
In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.